Dynasore, the dynamin inhibitor, modulates longitudinal bone growth in a hormetic manner.

This study demonstrates that the dynamin inhibitor dynasore exerts a hormetic effect on longitudinal bone growth in ex vivo mouse metatarsal cultures, where low doses stimulate elongation by enhancing matrix accumulation and mTORC1 signaling while blocking autophagy, whereas high doses impair growth by abolishing chondrocyte proliferation.

The Gist

Imagine your bones are like a construction site where a building is constantly being extended upward. This process, called endochondral ossification, relies on a team of specialized workers called chondrocytes (cartilage cells). These workers build a scaffold of cartilage, which is then replaced by hard bone, making you taller.

For these workers to do their job, they need a specific piece of machinery called Dynamin. Think of Dynamin as the "scissors" or the "zipper" of the cell. It's responsible for pinching off little bubbles (vesicles) that carry materials in and out of the cell. Without these scissors, the cell can't clean up its workspace, bring in new supplies, or get rid of waste efficiently.

The scientists in this study wanted to see what happens if they temporarily "break" these scissors using a chemical tool called Dynasore. They expected that breaking the scissors would stop the construction site from working. However, they discovered something surprising: it depends entirely on how much of the tool you use.

Here is the story of their discovery, explained through a simple analogy:

The "Goldilocks" Effect (Hormesis)

The researchers tested different amounts of Dynasore on mouse leg bones growing in a lab dish. They found a classic "Goldilocks" scenario, which scientists call hormesis:

1. Too Much (The High Dose): When they used a high concentration (220 µM), it was like taking a sledgehammer to the construction site. The scissors were completely destroyed. The workers (chondrocytes) panicked, stopped dividing, and many died. The bone growth stopped and even shrank.
2. Just Right (The Low Dose): When they used a tiny amount (40 µM), it was like gently jamming the scissors just enough to slow them down, but not break them. Surprisingly, this made the bones grow faster than normal!

How Did the "Jammed Scissors" Make Bones Grow?

You might wonder: If the cell's machinery is broken, why does it grow better?

The study found that the low dose of Dynasore changed the way the cells handled their "trash" and "supplies":

• The Traffic Jam: Normally, cells eat up old cartilage matrix (the scaffold) to recycle it. Dynasore jammed the "scissors," so the cells couldn't swallow and recycle the old material.
• The Pile-Up: Because the cells couldn't clean up, the cartilage matrix started piling up around them, like a room filling up with furniture that hasn't been thrown away yet.
• The Signal: This pile-up triggered a signal inside the cell (activating a pathway called mTORC1) that told the cell, "Hey, we have a lot of building material here! Let's get bigger and push the bone out."

It's like a factory that usually recycles its own waste. If you block the recycling truck, the factory floor gets cluttered. The manager sees all that raw material sitting there and decides, "Great! We have enough stuff to build a bigger wing right now!" So, the building expands, not because the workers are working harder, but because the waste removal is blocked, causing a buildup of materials that forces the structure to expand.

The Difference Between the Two Drugs

The researchers also compared Dynasore to another drug called Bafilomycin, which is known to make bones grow.

• Bafilomycin works by making the cells swell up (hypertrophy), like inflating a balloon.
• Dynasore (at low dose) didn't make the cells swell as much. Instead, it made the space between the cells fill up with extra cartilage material because the cells couldn't eat it.

The Takeaway

This study teaches us a valuable lesson about biology: More isn't always better, and less isn't always worse.

• High doses of this chemical are toxic and stop growth.
• Low doses act as a gentle nudge, tricking the cells into building bone faster by temporarily clogging their recycling system.

This is exciting because it suggests that in the future, we might be able to use very precise, low doses of similar chemicals to help children with growth disorders grow taller, or to help repair bones. However, the scientists warn that you have to be extremely careful with the dosage, because just a little too much turns a helpful nudge into a destructive hammer.

In short: By slightly jamming the cell's "scissors," the researchers accidentally discovered a way to make bones grow faster, proving that sometimes, a little bit of chaos in the cell's recycling bin can lead to a bigger building.

Technical Summary

1. Problem Statement

Longitudinal bone growth in mammals occurs via endochondral ossification, a complex process involving chondrocyte proliferation, differentiation, and extracellular matrix (ECM) remodeling. While the protein dynamin is known to be essential for membrane scission events (such as clathrin- and caveolin-mediated endocytosis, Golgi vesicle shuttling, and mitochondrial fission), its specific role in regulating chondrocyte function and bone elongation remains incompletely understood.

The study aims to investigate the effects of dynasore, a small-molecule, reversible dynamin inhibitor, on longitudinal bone growth. The researchers sought to determine if inhibiting dynamin could modulate bone growth and to elucidate the underlying cellular mechanisms, particularly given dynasore's potential off-target effects (e.g., on v-ATPase and actin remodeling).

2. Methodology

The study utilized an ex vivo murine metatarsal bone culture system, which preserves the native 3D architecture of the growth plate and allows for the study of chondrocytes at various differentiation stages.

• Experimental Model: Three-day-old C57BL/6 mouse metatarsals were cultured for up to 6 days.
• Treatment Groups:
  • Vehicle Control: DMSO.
  • Dynasore: Tested at four concentrations: 40 µM, 80 µM, 160 µM, and 220 µM.
  • Positive Control: Bafilomycin (8 nM), a known v-ATPase inhibitor that promotes bone overgrowth.
  • Combination: Dynasore (40 µM) + Bafilomycin.
• Assessment Techniques:
  • Gross Morphometry: Bone length measured via stereo-microscopy and ImageJ.
  • Histology & Histomorphometry: Safranin O/Fast Green staining to quantify growth plate zones (Resting, Proliferative, Hypertrophic) and ECM accumulation.
  • Cell Proliferation: EdU (5-ethynyl-2'-deoxyuridine) incorporation to label dividing cells.
  • Immunofluorescence:
    • Collagen Type X: To assess chondrocyte hypertrophy.
    • Phospho-RPS6: A marker for mTORC1 pathway activation.
    • SQSTM1 (p62): A marker for autophagy inhibition/lysosomal dysfunction.
  • Super-Resolution Microscopy (Airyscan): To visualize filamentous actin (F-actin) distribution at the plasma membrane.
  • Transmission Electron Microscopy (TEM): To analyze ultrastructural changes, specifically endocytic pit morphology and the presence of internalized ECM (collagen fibers).
• Statistics: One-way ANOVA with Tukey's test or Kruskal-Wallis with Dunn's test, depending on data normality.

3. Key Contributions

• Discovery of Hormesis: The study establishes that dynasore exerts a hormetic effect on bone growth: low doses stimulate elongation, while high doses inhibit it.
• Mechanistic Differentiation: The paper distinguishes the growth-promoting mechanism of dynasore from that of bafilomycin. While both inhibit v-ATPase and activate mTORC1, they achieve growth promotion through different cellular pathways (ECM accumulation vs. cell hypertrophy).
• Role of Endocytosis in Remodeling: The findings suggest that dynamin-mediated endocytosis is critical for ECM remodeling. Inhibiting this process leads to the accumulation of ECM in the extracellular space, driving bone elongation without necessarily increasing cell size.

4. Key Results

A. Dose-Dependent Hormetic Effect

• Low Dose (40 µM): Significantly increased longitudinal bone growth, comparable to the positive control (bafilomycin).
• High Dose (220 µM): Markedly reduced bone length and abolished chondrocyte proliferation, indicating cytotoxicity.
• Intermediate Doses (80–160 µM): Showed initial growth stimulation followed by a sharp decline, failing to sustain elongation.

B. Cellular and Histological Changes (40 µM Dynasore)

• Growth Plate Expansion: The length of the resting and proliferative zones (RZ+PZ) increased significantly.
• Proliferation vs. ECM: Despite the increased bone length, chondrocyte proliferation (EdU+) was reduced compared to controls.
• ECM Accumulation: There was a significant increase in the relative amount of ECM in the RZ, PZ, and hypertrophic zones.
• Hypertrophy: Unlike bafilomycin, 40 µM dynasore did not significantly increase chondrocyte hypertrophy (cell size) or Collagen Type X synthesis.

C. Molecular Pathways

• Autophagy & mTORC1: Low-dose dynasore (40 µM) caused accumulation of SQSTM1 (indicating blocked autophagy/lysosomal dysfunction) and increased phospho-RPS6 (indicating mTORC1 activation), similar to the effects of bafilomycin.
• High-Dose Effects: At 220 µM, both SQSTM1 and phospho-RPS6 levels were drastically decreased, correlating with cell death.

D. Ultrastructural Mechanisms

• F-Actin: Dynasore treatment expanded the thickness of the F-actin layer at the plasma membrane in resting, proliferative, and pre-hypertrophic chondrocytes.
• Endocytic Pits: TEM revealed that dynasore caused endocytic pits to become deeper and coated with electron-dense material, consistent with a blockage in vesicle scission (the primary function of dynamin).
• Internalized ECM: TEM images showed collagen fibers within endosomal compartments, particularly in bafilomycin-treated groups, suggesting that impaired endocytosis prevents the removal or remodeling of ECM, leading to its accumulation in the extracellular space.

5. Significance and Conclusion

• Novel Mechanism of Bone Growth: The study reveals that longitudinal bone growth can be stimulated not only by increasing cell proliferation or hypertrophy but also by impairing ECM remodeling via the inhibition of dynamin-mediated endocytosis. This leads to an accumulation of matrix that drives tissue expansion.
• Therapeutic Implications: The identification of a low-dose window (40 µM) where dynasore promotes growth without cytotoxicity suggests potential therapeutic avenues for treating growth disorders, provided the narrow therapeutic window and off-target effects (v-ATPase inhibition) are managed.
• Tool Validation: The research highlights the complexity of using dynasore as a research tool, as its effects are highly dose-dependent and involve both dynamin-dependent (endocytosis) and dynamin-independent (v-ATPase inhibition) mechanisms.
• Future Directions: The authors note that while dynasore shows promise in ex vivo models and has shown efficacy in osteoarthritis models in vivo, further research is needed to define the precise molecular targets and ensure safety for long-term in vivo application to stimulate bone growth.

In summary, this paper demonstrates that low-dose dynasore stimulates bone elongation by blocking chondrocyte endocytosis and autophagy, leading to ECM accumulation and mTORC1 activation, whereas high doses are cytotoxic.